Chilton Capital Management’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.52M Sell
4,306
-2,026
-32% -$722K 0.05% 109
2025
Q4
$2.07M Sell
6,332
-649
-9% -$206K 0.07% 102
2025
Q3
$1.97M Sell
6,981
-1,414
-17% -$410K 0.07% 105
2025
Q2
$2.34M Sell
8,395
-64,175
-88% -$18.2M 0.09% 97
2025
Q1
$22.6M Sell
72,570
-56
-0.1% -$16.5K 0.98% 40
2024
Q4
$18.9M Buy
72,626
+1,325
+2% +$393K 0.8% 43
2024
Q3
$23M Buy
71,301
+1,648
+2% +$539K 0.95% 41
2024
Q2
$21.8M Buy
69,653
+2,038
+3% +$599K 0.97% 37
2024
Q1
$19.2M Buy
67,615
+3,773
+6% +$1.1M 0.91% 44
2023
Q4
$18.4M Buy
63,842
+3,983
+7% +$1.09M 0.93% 46
2023
Q3
$16.1M Sell
59,859
-274
-0.5% -$68.4K 0.9% 50
2023
Q2
$13.4M Buy
60,133
+2,027
+3% +$470K 0.73% 58
2023
Q1
$14M Buy
58,106
+24
+0% +$5.89K 0.81% 57
2022
Q4
$15.3M Sell
58,082
-182
-0.3% -$48.8K 0.95% 42
2022
Q3
$13.1M Buy
58,264
+10,319
+22% +$2.5M 0.87% 50
2022
Q2
$11.7M Buy
+47,945
New +$11.7M 0.71% 58

Other funds holding AMGN

Chilton Capital Management's AMGN Position: Q1 2026 in Review

Chilton Capital Management reduced its Amgen (AMGN) stake by 32% in Q1 2026, selling an estimated $722K and leaving 4,306 shares worth $1.52M. The position accounts for 0.05% of the portfolio, ranked #109.

Chilton Capital Management first reported a position in AMGN in Q2 2022 and has held it in 16 quarters since. The position peaked at $23M in Q3 2024. 3,131 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Chilton Capital Management held 4,306 shares of Amgen worth $1.52M as of Q1 2026.
  • Chilton Capital Management sold 2,026 Amgen shares in Q1 2026, an estimated $722K.
  • Amgen made up 0.05% of Chilton Capital Management's portfolio in Q1 2026, its #109 holding.
  • Chilton Capital Management first reported a position in Amgen in Q2 2022 and has held it in 16 quarters since.
  • Chilton Capital Management's Amgen position peaked at $23M in Q3 2024.
  • 3,131 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Chilton Capital Management's 13F filing for Q1 2026, filed 11 May 2026.